← Evidence map

ArticleBreast cancer research and treatment2013

Prevalence of germline TP53 mutations in HER2+ breast cancer patients.

Michelle G Rath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

33 papers cite it

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 23580068